Breaking News Instant updates and real-time market news.

AGIO

Agios Pharmaceuticals

$34.42

-0.02 (-0.06%)

10:33
09/30/19
09/30
10:33
09/30/19
10:33

Agios data from Phase 3 ClarIDHy trial shows significant improvement in PFS

Agios Pharmaceuticals presented data from the global Phase 3 ClarIDHy trial of TIBSOVO in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation in a Presidential Symposium at the European Society for Medical Oncology Congress. Results from the ClarIDHy trial demonstrated a statistically significant improvement in progression-free survival by independent radiology review of 2.7 months among patients randomized to TIBSOVO compared with 1.4 months among placebo patients. The safety profile observed in the study was consistent with previously published data. "Advanced cholangiocarcinoma is an aggressive disease oftentimes characterized by rapid progression following multiple lines of therapy, and there are no currently approved treatments," said Ghassan Abou-Alfa, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center, who presented the data at ESMO. "The ClarIDHy study is the first randomized trial in previously treated IDH1 mutant cholangiocarcinoma patients and demonstrates that TIBSOVO provides significant improvement in PFS compared to placebo, while also showing a favorable trend in overall survival. These critical data also provide strong justification for genomic testing in cholangiocarcinoma patients where a targeted therapeutic approach may provide benefit."

  • 30

    Sep

  • 30

    Sep

  • 26

    Oct

AGIO Agios Pharmaceuticals
$34.42

-0.02 (-0.06%)

09/12/19
BMOC
09/12/19
INITIATION
Target $45
BMOC
Outperform
Agios Pharmaceuticals initiated with an Outperform at BMO Capital
BMO Capital analyst George Farmer initiated coverage of Agios Pharmaceuticals with an Outperform rating and a price target of $45. The analyst says the valuation on the stock is now "attractive" after shares became "oversold" following the company's failure to meet the high launch expectations for Tibsovo, but at current prices, he believes it reflects the base case scenario of Tibsovo's commercial potential. Farmer adds that some upside in shares is possible with rising Tibsovo awareness in the hematology-oncology community as well as the progress of mitapivat in its Phase 3 development for a rare blood disorder.
09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Agios Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
09/23/19
GUGG
09/23/19
UPGRADE
Target $55
GUGG
Buy
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
Guggenheim analyst Michael Schmidt upgraded Agios Pharmaceuticals (AGIO) to Buy from Neutral following a 20% year-to-date selloff in the shares, stating that the current valuation reflects no value beyond Tibsovo and Idhifa. Even with more conservative estimates, he believes Tibsovo alone is worth $35 per share and Idhifa royalties from Celgene (CELG) are worth $4, giving the stock a one-year "floor valuation" of $39 per share. Meanwhile, feedback from doctors highlights a moderate but "real" commercial opportunity in PKD for Mitapivat, said Schmidt, who set a $55 price target on Agios shares.
09/24/19
PIPR
09/24/19
NO CHANGE
Target $80
PIPR
Overweight
Agios Pharmaceuticals shares near a $30 'floor,' says Piper Jaffray
Following conversations with some of the "more bearish" investors, Piper Jaffray analyst Tyler Van Buren believes shares of Agios Pharmaceuticals are near a $30 "floor." Future isocitrate dehydrogenase franchise revenues plus cash provide "solid valuation support," while the company's pipeline is receiving "little credit," the analyst tells investors in a research note. Van Buren believes mitapivat, an allosteric PK-R activator, could be highly differentiated in a competitive hemolytic anemia space. Following a deep dive on the asset, the analyst reiterates an Overweight rating on Agios Pharmaceuticals with an $80 price target. He calls the stock one of his favorite names heading into 2020.

TODAY'S FREE FLY STORIES

NSCO

Nesco Holdings

$4.75

0.04 (0.85%)

20:44
11/11/19
11/11
20:44
11/11/19
20:44
Earnings
Nesco Holdings cuts FY19 revenue view to $255M-$262M from $278M »

One estimate $279.6M. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NSCO

Nesco Holdings

$4.75

0.04 (0.85%)

20:42
11/11/19
11/11
20:42
11/11/19
20:42
Earnings
Nesco Holdings reports Q3 EPS (45c), one estimate 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FTK

Flotek

$1.86

-0.1 (-5.10%)

20:29
11/11/19
11/11
20:29
11/11/19
20:29
Earnings
Flotek reports Q3 EPS (19c), one estimate (23c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RF

Regions Financial

$16.77

-0.1 (-0.59%)

20:27
11/11/19
11/11
20:27
11/11/19
20:27
Downgrade
Regions Financial rating change at BMO Capital »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

TSN

Tyson Foods

$82.70

0.12 (0.15%)

, ROK

Rockwell Automation

$180.00

2.25 (1.27%)

20:25
11/11/19
11/11
20:25
11/11/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TSN

Tyson Foods

$82.70

0.12 (0.15%)

ROK

Rockwell Automation

$180.00

2.25 (1.27%)

DHI

D.R. Horton

$52.65

1.535 (3.00%)

CBS

CBS

$39.21

1.09 (2.86%)

AAP

Advance Auto Parts

$168.41

1.17 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

  • 09

    Dec

RMTI

Rockwell Medical

$1.92

0.07 (3.78%)

20:01
11/11/19
11/11
20:01
11/11/19
20:01
Recommendations
Rockwell Medical analyst commentary at Piper Jaffray »

Rockwell Medical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

APYX

Apyx Medical

$7.22

0.24 (3.44%)

19:39
11/11/19
11/11
19:39
11/11/19
19:39
Recommendations
Apyx Medical analyst commentary at Piper Jaffray »

Apyx Medical price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 12

    Nov

FOE

Ferro

$12.58

0.07 (0.56%)

, APYX

Apyx Medical

$7.22

0.24 (3.44%)

18:59
11/11/19
11/11
18:59
11/11/19
18:59
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ferro…

FOE

Ferro

$12.58

0.07 (0.56%)

APYX

Apyx Medical

$7.22

0.24 (3.44%)

KEM

Kemet

$23.03

-0.51 (-2.17%)

ICUI

ICU Medical

$168.41

1.43 (0.86%)

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

GO

Grocery Outlet

$31.09

-0.06 (-0.19%)

CMLS

Cumulus Media

$13.59

0.07 (0.52%)

FGEN

FibroGen

$35.37

-6.24 (-15.00%)

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

BREW

Craft Brew

$7.33

0.06 (0.83%)

LYV

Live Nation

$64.47

1.31 (2.07%)

FLNT

Fluent

$2.54

0.11 (4.53%)

ASUR

Asure Software

$9.20

0.01 (0.11%)

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

HBM

Hudbay Minerals

$3.66

-0.09 (-2.40%)

FPI

Farmland Partners

$6.66

-0.125 (-1.84%)

RETA

Reata Pharmaceuticals

$213.52

1.48 (0.70%)

JCOM

j2 Global

$100.62

0.23 (0.23%)

PCG

PG&E

$6.24

-0.23 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

  • 09

    Dec

  • 07

    Jan

CRL

Charles River

$131.58

1.19 (0.91%)

18:57
11/11/19
11/11
18:57
11/11/19
18:57
Hot Stocks
Charles River CEO: We are pleased with the demand curve »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$6.24

-0.23 (-3.55%)

18:44
11/11/19
11/11
18:44
11/11/19
18:44
Periodicals
PG&E offers $13.5B in compensation to victims of CA fires, Bloomberg says »

PG&E is offering to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 07

    Jan

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:27
11/11/19
11/11
18:27
11/11/19
18:27
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Kemet up 14.7% to $26.40…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NCLH

Norwegian Cruise Line

$51.90

0.07 (0.14%)

18:23
11/11/19
11/11
18:23
11/11/19
18:23
Hot Stocks
Norwegian Cruise Line CEO: North American consumer is alive and well »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOE

Ferro

$12.58

0.07 (0.56%)

18:23
11/11/19
11/11
18:23
11/11/19
18:23
Earnings
Ferro reports Q3 adjusted EPS 35c, consensus 28c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:09
11/11/19
11/11
18:09
11/11/19
18:09
Hot Stocks
Yageo to acquire Kemet for $27.20 per share in cash, or $1.8B »

Yageo and Kemet announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PAR

Par Technology

$30.23

1.07 (3.67%)

18:08
11/11/19
11/11
18:08
11/11/19
18:08
Recommendations
Par Technology analyst commentary at Jefferies »

Par Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:06
11/11/19
11/11
18:06
11/11/19
18:06
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Yageo to acquire Kemet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CSX

CSX

$73.93

-0.08 (-0.11%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Downgrade
CSX rating change at Deutsche Bank »

CSX downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TDW

Tidewater

$17.14

-0.34 (-1.95%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Earnings
Tidewater reports Q3 adjusted EPS (99c), may not compare to consensus (10c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UNVR

Univar

$23.87

-0.08 (-0.33%)

17:57
11/11/19
11/11
17:57
11/11/19
17:57
Hot Stocks
Univar named EMEA distributor for Kaopolite Abrasive in Europe »

Univar B.V., a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXRT

NexPoint Residential

$46.48

0.44 (0.96%)

17:56
11/11/19
11/11
17:56
11/11/19
17:56
Hot Stocks
NexPoint Residential acquires three-property portfolio in Las Vegas for $241M »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Breaking Hot Stocks news story on DXC Technology »

DXC reverses course, now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Fluent drops over 22% after reporting Q3 results, lowers FY19 revenue view »

Shares of Fluent are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Hot Stocks
DXC Technology to pursue strategic alternatives for three businesses »

Says as part of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Earnings
Fluent lowers FY19 revenue view to $87M-$88M from $93M-$98M »

Sees adjusted EBITDA is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.